<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253223</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00102920</org_study_id>
    <nct_id>NCT04253223</nct_id>
  </id_info>
  <brief_title>A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib</brief_title>
  <official_title>A Phase I/Ib Pilot Study to Determine the Safety and Efficacy of a Human Anti-glucagon Receptor Antibody (REMD-477) in Controlling Severe Hyperglycemia Due to Copanlisib in Patients With Relapsed or Refractory Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      REMD-477 (Volagidemab) is a human anti-glucagon receptor antibody. Its proposed mechanism of&#xD;
      action in controlling hyperglycemia is by blocking glucagon receptor (GCGR) signaling. In&#xD;
      this way, it increases hepatic glucose uptake, decreases hepatic glycogenolysis and&#xD;
      gluconeogenesis, increases glycogen synthesis, and ultimately decreases blood glucose levels.&#xD;
      This protocol will test the hypotheses that REMD-477 is safe and tolerable in patients with&#xD;
      severe hyperglycemia on copanlisib and that it decreases the risk of severe hyperglycemia in&#xD;
      patients receiving copanlisib for relapsed refractory lymphoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor accrual&#xD;
  </why_stopped>
  <start_date type="Actual">April 7, 2020</start_date>
  <completion_date type="Actual">May 5, 2021</completion_date>
  <primary_completion_date type="Actual">May 5, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>22 days</time_frame>
    <description>Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase inhibitor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>22 days</time_frame>
    <description>Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Function Tests (LFT) units per liter (u/L)</measure>
    <time_frame>22 days</time_frame>
    <description>Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Glucose measurements</measure>
    <time_frame>22 days</time_frame>
    <description>Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse beats per minute</measure>
    <time_frame>22 days</time_frame>
    <description>Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>breathing Rate breaths per minute</measure>
    <time_frame>22 days</time_frame>
    <description>Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose levels</measure>
    <time_frame>22 days</time_frame>
    <description>Determine efficacy of REMD-477 in preventing copanlisib induced hyperglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin levels</measure>
    <time_frame>22 days</time_frame>
    <description>Determine efficacy of REMD-477 in preventing copanlisib induced hyperglycemia</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Hyperglycemia Drug Induced</condition>
  <arm_group>
    <arm_group_label>REMD-477</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REMD-477 (human IgG2 anti-glucagon receptor antibody Volagidemab) will be administered as a subcutaneous injection for three weekly doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>REMD-477</intervention_name>
    <description>REMD-477 will be administered as a subcutaneous injection for three weekly doses</description>
    <arm_group_label>REMD-477</arm_group_label>
    <other_name>Volagidemab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Relapsed or refractory lymphoma (Grade 1, 2, 3A)&#xD;
&#xD;
          -  Received 2 or more prior lines of systemic therapy for lymphoma&#xD;
&#xD;
          -  Experienced glucose &gt;250 mg/dL after copanlisib infusion for treatment of lymphoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of histologic transformation&#xD;
&#xD;
          -  Follicular Lymphoma Grade 3B&#xD;
&#xD;
          -  Active CNS involvement by malignancy&#xD;
&#xD;
          -  Elevated AST or ALT &gt; 5x ULN at Screening&#xD;
&#xD;
          -  Unmanageable sensitivity to mammalian-derived drug preparations, or to humanized or&#xD;
             human antibodies; managed sensitivities to agents such as obinutuzumab or rituximab or&#xD;
             similar agents are not exclusionary&#xD;
&#xD;
          -  History of drug or alcohol abuse within the last 6 months&#xD;
&#xD;
          -  History or family history of pancreatic neuroendocrine tumors or multiple endocrine&#xD;
             neoplasia&#xD;
&#xD;
          -  History or family history of pheochromocytoma&#xD;
&#xD;
          -  Other gastrointestinal, cardiac, renal and CNS (i.e. hypoglycemia unawareness)&#xD;
             conditions specific to diabetes that would pose additional risk to subject's safety or&#xD;
             interfere with the study evaluation, procedures or completion in the opinion of the&#xD;
             treating physician.&#xD;
&#xD;
          -  Female subject is pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Herbert Lyerly</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hyperglycemia</keyword>
  <keyword>lymphoma</keyword>
  <keyword>anti-glucagon receptor antibody</keyword>
  <keyword>glucagon receptor</keyword>
  <keyword>Volagidemab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Volagidemab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

